Bulet SR 150mg Tablet is a prescription medicine containing bupropion hydrochloride 150mg in a sustained-release (SR) formulation. Bupropion belongs to a class of medicines known as aminoketone antidepressants and is used in appropriate patients for the treatment of major depressive disorder (MDD). Current Indian listings identify Bulet SR 150 as a 150mg bupropion tablet marketed by Tripada Lifecare Pvt Ltd.

Bupropion SR may also be used in appropriately prescribed smoking-cessation programs to help reduce nicotine cravings and withdrawal-related symptoms. The exact approved indication can depend on the specific bupropion formulation and local product labeling, so Bulet SR should be used only for the indication prescribed by a healthcare professional. Sustained-release bupropion products are specifically used as an aid to smoking cessation in relevant labeling.

The exact antidepressant mechanism of bupropion is not fully understood. Current prescribing information states that its action is thought to involve noradrenergic and dopaminergic pathways. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine and does not significantly inhibit serotonin reuptake or monoamine oxidase.

Bulet SR tablets should be swallowed whole. Sustained-release tablets should not be crushed, chewed or divided because damaging the release mechanism can cause bupropion to be released too quickly and may increase adverse effects, including seizure risk. Bupropion SR may be taken with or without food.

The exact dose and frequency must be determined by the prescribing clinician. With bupropion, doses are generally increased gradually because seizure risk is dose-related. Patients should not take an extra tablet to compensate for a missed dose.

Common adverse effects associated with bupropion SR include dry mouth, insomnia, nausea, headache, dizziness, sweating, tremor, anxiety or agitation, constipation and rash.

Important safety considerations include seizures, increased blood pressure, activation of mania or hypomania, serious neuropsychiatric reactions and suicidal thoughts or behavior in younger patients taking antidepressants. Bupropion SR is contraindicated in people with a seizure disorder, current or previous bulimia or anorexia nervosa, certain abrupt alcohol/sedative withdrawal situations, and with certain MAO inhibitors.

Product Information

Brand Name: Bulet SR 150mg Tablet
Generic Name: Bupropion Hydrochloride
Strength: 150 mg
Formulation: Sustained Release (SR)
Dosage Form: Tablet
Route: Oral
Drug Class: Aminoketone Antidepressant
Primary Established Use: Major depressive disorder
Additional Clinical Use of Bupropion SR: Smoking-cessation support when appropriately prescribed
Marketer: Tripada Lifecare Pvt Ltd
Prescription Status: Prescription medicine

Bulet SR 150mg Tablet (Bupropion Hydrochloride)

Name: Bulet SR 150mg Tablet (Bupropion Hydrochloride)
Brand: Tripada Lifecare
Price: 71 USD
Availability: InStock

$71.00

Pack Size

Quantity

Bulet SR 150mg Tablet contains bupropion and is used primarily as an antidepressant for major depressive disorder.

Bupropion SR formulations may also be prescribed as part of a smoking-cessation treatment program, where they can help reduce nicotine cravings and withdrawal symptoms.

Because indication can differ between bupropion formulations and local labels, patients should use Bulet SR only for the condition for which it has specifically been prescribed.
The main benefit of Bulet SR is helping manage depressive symptoms by influencing norepinephrine- and dopamine-related signaling in the brain.

For patients with major depressive disorder, bupropion treatment may help improve symptoms such as depressed mood, reduced interest and other features of depression over time.

When sustained-release bupropion is prescribed for smoking cessation, it may help reduce cravings and nicotine-withdrawal symptoms, supporting a structured quit-smoking program. Counseling and behavioral support remain important components of smoking cessation.

Response differs between individuals, and antidepressant benefits may take time to develop.
Bulet SR should be taken exactly according to the dose and schedule prescribed by a healthcare professional.

Because it is a sustained-release tablet, it should be swallowed whole and should not be crushed, chewed or divided. Bupropion SR can be taken with or without food.

When more than one SR dose is prescribed in a day, appropriate spacing between doses is important. Current SR antidepressant labeling uses an interval of at least 8 hours between successive doses at twice-daily dosing.

If a dose is missed, do not take an extra tablet to make up for it because excessive bupropion exposure can increase seizure risk. Follow the next scheduled dose unless the prescriber advises otherwise.
Bupropion appears to work mainly through norepinephrine and dopamine pathways in the brain, although its exact antidepressant mechanism is not fully known.

Bupropion weakly inhibits the neuronal reuptake of norepinephrine and dopamine, which can increase signaling involving these neurotransmitters. It does not significantly inhibit serotonin reuptake and is not a monoamine oxidase inhibitor.

For SEO/GEO entity understanding, the clinically accurate relationship is:

Bulet SR → Bupropion Hydrochloride → Sustained Release → Norepinephrine/Dopamine pathways → Antidepressant effect

Avoid describing it simply as a drug that “increases dopamine” because its pharmacology and clinical effect are more nuanced.
Common bupropion SR side effects include dry mouth, insomnia, nausea, headache, dizziness and increased sweating.

Other reported effects include anxiety or agitation, tremor, constipation, rash, palpitations and changes in appetite.

One particularly important risk is seizure, and the risk increases with higher doses and certain medical conditions or interacting medicines. Bupropion is contraindicated in people with seizure disorders and in those with a current or previous diagnosis of bulimia or anorexia nervosa.

Bupropion may also increase blood pressure. As with other antidepressants, younger patients should be monitored for new or worsening suicidal thoughts, unusual changes in mood or behavior, agitation, mania or other significant neuropsychiatric changes, particularly after starting treatment or changing the dose.

Seek prompt medical care for a seizure, severe allergic reaction, severe behavioral or mood change, suicidal thoughts or other serious symptoms.